AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.
News|Articles|July 13, 2026
Diabetic eye disease: Developments that defined the first half of 2026
Author(s)Kassi Filkins
A recap of the FDA approvals, phase 3 readouts, and pipeline data that shaped diabetic eye disease care in the first half of 2026.
Advertisement
Advertisement
The first half of 2026 brought a steady drumbeat of regulatory and clinical news across the diabetic eye disease space, from a landmark autonomous AI screening clearance to phase 3 data challenging the decades-old standard of care for proliferative DR. Below is an overview of key developments from the first six months of 2026 in diabetic macular edema (DME) and diabetic retinopathy (DR).
Related to this article
Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.
Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.
OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.
Advertisement
Advertisement